Table 1.
The anti-TMV activity of I-1–I-10, II-1–II-5 and III-1–III-4.
| Compounds | Concentration (μg/mL) | Relative inhibition rate (%)a | ||
|---|---|---|---|---|
| Inactivation effect | Curative effect | Protection effect | ||
| I-1 | 500 | 32 ± 2 | ||
| I-2 | 500 | 36 ± 1 | ||
| I-3 | 500 | 34 ± 3 | ||
| I-4 | 500 | 35 ± 3 | ||
| I-5 | 500 | 42 ± 4 | ||
| I-6 | 500 | 38 ± 2 | ||
| I-7 | 500 | 37 ± 2 | ||
| I-8 | 500 | 38 ± 3 | ||
| I-9 | 500 | 54 ± 1 | 54 ± 4 | 55 ± 3 |
| 100 | 24 ± 1 | 15 ± 1 | 20 ± 1 | |
| I-10 | 500 | 51 ± 1 | 56 ± 2 | 47 ± 2 |
| 100 | 21 ± 1 | 18 ± 2 | 17 ± 2 | |
| II-1 | 500 | 23 ± 5 | ||
| II-2 | 500 | 43 ± 1 | 44 ± 4 | 40 ± 2 |
| 100 | 24 ± 2 | 15 ± 1 | 0 | |
| II-3 | 500 | 39 ± 3 | ||
| II-4 | 500 | 41 ± 5 | 43 ± 2 | 46 ± 2 |
| 100 | 26 ± 1 | 0 | 25 ± 1 | |
| II-5 | 500 | 54 ± 1 | 52 ± 2 | 51 ± 4 |
| 100 | 25 ± 2 | 28 ± 1 | 23 ± 1 | |
| III-1 | 500 | 30 ± 2 | ||
| III-2 | 500 | 50 ± 1 | 53 ± 1 | 59 ± 4 |
| 100 | 25 ± 2 | 20 ± 2 | 28 ± 1 | |
| III-3 | 500 | 38 ± 3 | ||
| III-4 | 500 | 57 ± 1 | 59 ± 3 | 51 ± 4 |
| 100 | 20 ± 2 | 26 ± 1 | 21 ± 1 | |
| Resveratrolb | 500 | 50 ± 1 | 43 ± 2 | 45 ± 2 |
| 100 | 13 ± 1 | 15 ± 1 | 18 ± 1 | |
| Ribavirinb | 500 | 38 ± 2 | 37 ± 1 | 40 ± 1 |
| 100 | 11 ± 2 | 13 ± 1 | 12 ± 1 | |
aAverage of three replicates. All results are expressed as the mean ± standard deviation (SD). Prominent activity data were presented in italics.
bPositive control.